RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Olema Pharmaceuticals Stock

Olema Pharmaceuticals P/E 2024

Olema Pharmaceuticals P/E

-3.85

Ticker

OLMA

ISIN

US68062P1066

WKN

A2QGWT

As of Nov 29, 2024, Olema Pharmaceuticals's P/E ratio was -3.85, a 43.12% change from the -2.69 P/E ratio recorded in the previous year.

The Olema Pharmaceuticals P/E history

Olema Pharmaceuticals Aktienanalyse

What does Olema Pharmaceuticals do?

Olema Pharmaceuticals Inc. is a biotechnology company specializing in the development of new drugs for the treatment of cancer. The company was founded in 2013 by Sean P. Bohen and is headquartered in San Francisco, California. The history of Olema Pharmaceuticals began with Bohen recognizing the importance of the Estrogen Receptor-Alpha (ER-Alpha) in the development of breast cancer. He founded the company to specifically develop drugs that block the ER-Alpha receptor and contribute to more effective treatment of breast cancer. The business model of Olema Pharmaceuticals is based on the discovery and development of new drugs and de novo treatments for fighting cancer. The company is focused on better understanding the molecular mechanisms of cancer growth to develop more targeted therapies. Olema has several divisions in the research and development of new drugs, particularly for the treatment of breast cancer. The company is focused on its proprietary platform for the identification and development of small molecules that can selectively bind to the ER-Alpha receptor. By focusing on specific target molecules, the company aims to minimize side effects and maximize the effectiveness of its drugs. The first product Olema Pharmaceuticals has launched is a medication called OP-1250. OP-1250 is a small molecule specifically designed to combat breast cancer. It targets the ER-Alpha receptor and aims to block it to stop the growth of breast cancer cells. In Olema Pharmaceuticals' pipeline, there are several other drugs in the clinical development phase. OP-2456, another drug for the treatment of breast cancer, is in Phase II of clinical trials. Olema is also developing compounds for other types of cancer and has a portfolio of about 60 other candidates in the research phase. The company has also formed partnerships with other biotechnology companies and pharmaceutical companies to expand its research and achieve its goals. For example, Olema collaborates with Janssen Biotech, a company of Johnson & Johnson. Overall, Olema Pharmaceuticals aims to develop new and innovative therapy options for the treatment of cancer. By focusing on specific target molecules, the company hopes to develop more effective therapies with fewer side effects. Olema Pharmaceuticals is dedicated to expanding its portfolio of cancer drugs and improving the lives of many people. Olema Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Olema Pharmaceuticals's P/E Ratio

The Price to Earnings (P/E) Ratio of Olema Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Olema Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Olema Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Olema Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Olema Pharmaceuticals stock

What is the price-to-earnings ratio of Olema Pharmaceuticals?

The price-earnings ratio of Olema Pharmaceuticals is currently -3.85.

How has the price-earnings ratio of Olema Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Olema Pharmaceuticals has increased by 43.12% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Olema Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Olema Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Olema Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Olema Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Olema Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Olema Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Olema Pharmaceuticals?

Some factors that influence the price-earnings ratio of Olema Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Olema Pharmaceuticals pay?

Over the past 12 months, Olema Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Olema Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Olema Pharmaceuticals?

The current dividend yield of Olema Pharmaceuticals is .

When does Olema Pharmaceuticals pay dividends?

Olema Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Olema Pharmaceuticals?

Olema Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Olema Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Olema Pharmaceuticals located?

Olema Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Olema Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Olema Pharmaceuticals from 11/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/29/2024.

When did Olema Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/29/2024.

What was the dividend of Olema Pharmaceuticals in the year 2023?

In the year 2023, Olema Pharmaceuticals distributed 0 USD as dividends.

In which currency does Olema Pharmaceuticals pay out the dividend?

The dividends of Olema Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Olema Pharmaceuticals

Our stock analysis for Olema Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Olema Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.